Profusa (PFSA) Net Income towards Common Stockholders Growth (1y) (2023 - 2026)
Profusa (PFSA) Net Income towards Common Stockholders Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.57 Bn | 193.97 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 127.25 Bn | 123.77 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 118.81 Bn | 109.59 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 73.35 Bn | 72.81 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 34.28 Bn | 32.34 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 33.75 Bn | 31.64 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.03 Bn | 22.55 Bn | 684.20 Mn | 12.92% |
| 10 | Profusa | 123,634.76 | -251,365.24 | - | -263.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -311.28% |
| Dec 31, 2025 | 36.84% |
| Sep 30, 2025 | -24,839.79% |
| Jun 30, 2025 | -1,962.17% |
| Mar 31, 2025 | -36.53% |
| Dec 31, 2024 | -3,666.20% |
| Sep 30, 2024 | 129.48% |
| Jun 30, 2024 | -395.26% |
| Mar 31, 2024 | -343.65% |
| Dec 31, 2023 | 123.58% |
| Sep 30, 2023 | -122.34% |
| Jun 30, 2023 | -48.33% |
| Mar 31, 2023 | -57.76% |